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Introduction
Obesity is a global problem that is increasing at epidemic 
rates. According to the World Health Organization, in 2016, 
more than 1.9 billion adults were overweight, and more than 
650 million are classified as truly obese1. Obesity is a risk fac-
tor for health as it is related to serious diseases such as type 2 
diabetes mellitus, cardiovascular and Alzheimer’s disease, and 
even some types of cancer2. Carnitine palmitoyltransferase 1 
(CPT1), is an enzyme belonging to the family of carnitine acyl-
transferases whose function is to transport the long chain fatty 
acids coupled with coenzyme A (LCFA-CoA), from the cytosol 
to the mitochondria where LCFA are β-oxidized to satisfy the 
need for the energy required in the body3. Energy homeostasis 
is specifically regulated by the hypothalamic neurons, which 
can detect increased LCFA levels and regulate food intake by 
modulating appetite4. The inhibition of hypothalamic CPT1 in-
creases cytosolic LCFA-CoA levels of hypothalamic neurons, 
which triggers the mRNA expression of anorexigenic neuro-
peptides and decreases the mRNA expression of orexigenic 
neuropeptides. This is a signal of satiety and nutrient abun-
dance which produces a loss of appetite5. The activity of CPT1 
can be modulated by its physiological inhibitor malonyl-CoA, 
which controls the balance between synthesis and oxidation 
of LCFAs6.
C75 is an α-methylene-γ-butyrolactone, which acts as an 
appetite suppressor when it is coupled with coenzyme A (C75-
CoA) by inhibiting CPT1 enzyme. Studies in vivo showed that 
injection of free C75 is transformed into C75-CoA and causes 
suppression of appetite and loss of body weight in animals5. 
The majority of the studies were carried out with a racemic 
mixture of C75, however (+)-C75-CoA enantiomer is responsi-
ble for the strong inhibition of CPT1 and a decrease in food in-
take in animals7.  Herein, we show the synthesis of some race-
mic C75 derivatives and the evaluation of their CPT1 inhibitory 
activity with the aim of better understanding the structural 
requirements for stronger CPT1 inhibition.
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Abstract: Carnitine Palmitoyltransferase (CPT1) is an enzyme that catalyzes the transport of fatty acids from the cytosol into 
the mitochondria. CPT1 inhibition in the hypothalamus increases fatty acid levels, which produces an increased expression 
of anorexigenic neuropeptides, a sign of satiety. C75 acts as an antiobesity predrug. In vivo C75, is converted into C75-CoA 
adduct, which is a potent inhibitor of CPT1 and produces a loss of appetite and body weight. In this work, we present three new 
derivatives of C75, where the carboxylic group is replaced by a carnitine unit, malonic group, and a hydroxyl group with changes 
from trans to cis relative stereochemistry. Our results suggest that introducing a bigger group than carboxylic in β position or cis 
relative configuration of the lactone leads to a decrease of CPT1 inhibitory activity.
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Materials and methods
The organic synthesis was carried out by standard pro-
cedures. A thin layer, column chromatography, melting point, 
NMR, IR, and high-resolution mass spectrometry were used 
to characterize and identify the obtained products (data not 
shown).
The anorexigenic activity of the C75 derivatives was tes-
ted in vivo in Sprague-Dawley rats, with intracerebroventricu-
lar (i.c.v.) administrations5. To perform in vitro CPT1 inhibitory 
studies, all derivatives of C75 were previously converted into 
coenzyme A adducts. The determination of the CPT1 inhibitory 
activity was carried out using a radiometric method7.
Results
We started the design of new derivatives of C75 with 
changes in the β position of lactone. Since malonyl-CoA is a 
physiological inhibitor of CPT1 and carnitine is a substrate of 
that enzyme, we synthesized two derivatives which substitute 
carboxylic group by malonic and carnitine moiety. On the other 
hand, the importance of relative lactone stereochemistry is 
unknown, and cis-C75 is unstable due to the migration of exo-
cyclic double bond into endocyclic. Thus, we synthesized an 
alcoholic derivative of cis-C75, which can be compared with 
the already reported trans compound (UB006)8.
The synthesis of the C75 derivatives is initiated by the re-
duction using BH3: SMe2 of the advanced acid mixture reported 
previously in the synthesis of C759 with a protected double 
bond as selenoether.
The mixture of alcoholic diastereomers could be separa-
ted with fewer difficulties than acids and were the straining 
point in the synthesis of designed derivatives. The final alco-
holic product (±)-cis-UB006 where obtained straightforwardly 
by recovering the exocyclic double bond in oxidative conditions.
The malonic derivative (±)-UB001 was synthesized in 
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Figure 1. Synthesis of three new derivatives of C75.
Figure 2. Preparation of the adducts of derivatives with coenzyme A.
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three steps, condensation of starting trans alcohol with a mo-
noprotected malonic acid using carbodiimide and 4-DMAP as a 
catalyst. Next, the benzyl group was removed with TFA. Fina-
lly, under oxidizing conditions, the double bond of the lactone 
was recovered obtaining the derivative UB001.
The last derivatives with carnitine moiety were obtained 
in two steps. The first hydroxyl group was replaced by bromi-
ne using Appel reaction conditions, and then L-carnitine was 
coupled. The reaction required relatively high temperature and 
in the same step double bond was formed indicating that se-
lenoether is unstable during the heating. The product called 
UB079 is a mixture of diastereomers due using enantiopure 
carnitine, and this mixture was used for preliminary CPT1 ac-
tivity studies. 
To test the inhibitory power in vitro of the synthesized de-
rivatives, these must be previously converted into their coen-
zyme A adducts. The synthesis of the coenzyme A adduct is 
carried out by mixing the derivative and the HSCoA in D2O at 
a pH ~ 8 in an NMR tube and reaction was finished before 4h 
in all cases. 
Once coenzyme A adduct of the derivatives was prepared, 
the inhibitory activity of these compounds was tested in vitro. 
The malonic derivative, UB001-CoA showed a decrease in the 
inhibitory activity concerning C75. Whereas, the carnitine de-
rivative, UB079-CoA, was inactive in the inhibition of CPT1 at 
concentrations IC50 > 50 mM. On the other hand, it is observed 
that the alcoholic analogous, compound (±)-cis-UB006-CoA, 
present much worst inhibitory capacity than C75-CoA and 
trans UB006-CoA.
Of the three derivatives presented, the compound UB001-
CoA was selected for in vivo study.  For the analysis, the free 
C75 (positive control) and UB001 were administered by i.c.v. 
Injection as well as a vehicle without any drug as a control. 
Then, body weight and food intake were measured. The 
UB001, which present about 10-fold decrease of inhibitory in 
vitro activity, compared to C75, present complete loss of appe-
tite suppressing activity (Figure 4B) when administered at the 
same concentration as C75 i.c.v. and did not cause a loss of 
body weight (Figure 4A).
Figure 3. Effect of C75 derivatives on CPT1 activity was assayed in the presence of increasing concentrations of UB001-CoA, 
UB079-CoA (A), UB006-CoA, cis-UB006-CoA (B). C75-CoA was used as a positive control. The results are represented as the 
mean ± S.E.M.
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Figure 4. Effect of UB001 on body weight and food intake. (A). Accumulated food intake was measured after 1, 2, and 22 h after 
the injection (B). The results are expressed as the average ± S.E.M.
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Conclusions
WWe conclude that the groups tested in the β position of 
the derivatives, the carnitine unit in UB079 and the malonic 
group in UB001 cause the loss of CPT1 inhibitory activity and 
seems that active center of that enzyme does not support bul-
kier group than carboxylic on the β position of the lactone. On 
the other hand, the change of trans to cis relative stereoche-
mistry produces a loss of CPT1 inhibitory activity.
These new findings suggest that the length of the spacer 
between coenzyme A and the carboxylic group should be less 
than seven bonds, and it will be considered in future studies of 
CPT1 inhibitors derivatives of C75.
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